There are 717 resources available
303MO - Single-cell analysis reveals the interaction between M2 macrophages and NK cells underlying immune types associated with cancer immunotherapy response
Presenter: Anlin Li
Session: Mini oral session on Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
70MO - Efficacy and safety of envafolimab (KN035) in advanced tumours with mismatch-repair deficiency
Presenter: Jian Li
Session: Mini oral session on Developmental and precision medicine
Resources:
Abstract
Webcast
71MO - OBI-833 was safe and immunogenic, without treatment-related SAEs, in a phase I dose-escalation trial
Presenter: Her-shyong Shiah
Session: Mini oral session on Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
72MO - Selinexor in combination with standard chemotherapy in patients with advanced solid tumours: Results of an open label, single-center, multi-arm phase Ib study
Presenter: Kyaw Thein
Session: Mini oral session on Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
115MO - Long-term efficacy, tolerability and overall survival in patients (pts) with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib: NAVIGATOR phase I trial update
Presenter: Yoon-Koo Kang
Session: Mini oral session on Gastrointestinal tumours 1
Resources:
Abstract
Slides
Webcast
116MO - Efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements: FOENIX-CCA2
Presenter: Junji Furuse
Session: Mini oral session on Gastrointestinal tumours 1
Resources:
Abstract
Slides
Webcast
117MO - Comparison of survival and patterns of recurrence in gastric neuroendocrine carcinoma, mixed adenoneuroendocrine carcinoma and adenocarcinoma: A multicenter study from China
Presenter: Jun-Peng Lin
Session: Mini oral session on Gastrointestinal tumours 1
Resources:
Abstract
Slides
Webcast
378MO - EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%
Presenter: Ahmet Sezer
Session: Mini oral session on Thoracic cancers
Resources:
Abstract
Slides
Webcast
379MO - Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
Presenter: Jun Ho Ji
Session: Mini oral session on Thoracic cancers
Resources:
Abstract
Slides
Webcast
380MO - A phase II trial of atezolizumab, bevacizumab, pemetrexed and carboplatin combination for metastatic EGFR-mutated NSCLC after TKI failure
Presenter: Tai Chung Lam
Session: Mini oral session on Thoracic cancers
Resources:
Abstract
Slides
Webcast